NWBO Northwest Biotherapeutics, Inc.
-
Northwest Biotherapeutics Reported Earnings
Friday, August 14, 2026 · 12:00 AM ET
Northwest Biotherapeutics (NWBO) reported a loss of $0.01 per share on revenue of $0.81 million for the . . Revenue grew 516.03% on a year-over-year basis.
Northwest Biotherapeutics Inc is a development stage biotechnology company engaged in the development of immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies.
Reported Earnings
($0.01)
Earnings Whisper®
—
Consensus Estimate
—
Earnings Surprise
Earnings Growth
Reported Revenue
$0.81M
Revenue Estimate
—
Revenue Surprise
Revenue Growth